Literature DB >> 26287867

Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis.

.   

Abstract

Entities:  

Year:  2015        PMID： 26287867     DOI： 10.1056/NEJMx150012

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  Idiopathic pulmonary fibrosis: past, present, future-a review from Talmadge King's ATS 2016 presentation.

Authors:  S Clark Berngard; Kamyar Afshar
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

2.  Characterization of the PF-ILD phenotype in patients with advanced pulmonary sarcoidosis.

Authors:  M C Schimmelpennink; D B Meek; A D M Vorselaars; L C M Langezaal; C H M van Moorsel; J J van der Vis; M Veltkamp; J C Grutters
Journal:  Respir Res       Date:  2022-06-25

Review 3.  Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy.

Authors:  Juan Wang; Sumera Ilyas
Journal:  Expert Opin Investig Drugs       Date:  2020-12-28       Impact factor: 6.206

4.  Characteristics and Prognostic Impact of Pneumonitis during Systemic Anti-Cancer Therapy in Patients with Advanced Non-Small-Cell Lung Cancer.

Authors:  Daichi Fujimoto; Ryoji Kato; Takeshi Morimoto; Ryoko Shimizu; Yuki Sato; Mariko Kogo; Jiro Ito; Shunsuke Teraoka; Kazuma Nagata; Atsushi Nakagawa; Kojiro Otsuka; Keisuke Tomii
Journal:  PLoS One       Date:  2016-12-22       Impact factor: 3.240

5.  Comparison of FDA Approved Kinase Targets to Clinical Trial Ones: Insights from Their System Profiles and Drug-Target Interaction Networks.

Authors:  Jingyu Xu; Panpan Wang; Hong Yang; Jin Zhou; Yinghong Li; Xiaoxu Li; Weiwei Xue; Chunyan Yu; Yubin Tian; Feng Zhu
Journal:  Biomed Res Int       Date:  2016-07-28       Impact factor: 3.411
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.